Evaluation of Pharmacokinetics and Safety of Intravenous ABBV-969 in Adults with Metastatic Castration-Resistant Prostate Cancer

The primary objective of this study is to assess the **adverse events** associated with the intravenous infusion of ABBV-969 in adult participants diagnosed with **metastatic castration-resistant prostate cancer**. This evaluation is clinically relevant as it aims to determine the safety profile of ABBV-969, which is crucial for understanding potential risks and managing patient care effectively in this population. The study also seeks to understand how ABBV-969 is distributed and metabolized in the body, providing insights into its pharmacokinetics, which is essential for optimizing dosing regimens and improving therapeutic outcomes.

The clinical trial involves a total of **110 participants** diagnosed with **Prostate Cancer**, specifically focusing on those with **Metastatic Castration-Resistant Prostate Cancer**. The study population is exclusively male, as indicated by the selection criteria, and includes individuals within the age categories corresponding to middle-aged and older adults. Participants were selected based on their health status, ensuring they are not part of a vulnerable population. Lifestyle factors such as diet, physical activity, and habits were not specified in the available data. The sponsor did not provide detailed information regarding the main objective of the trial or specific inclusion criteria.

The clinical trial is designed to evaluate the safety and pharmacokinetics of the investigational drug ABBV-969 in adult participants diagnosed with **metastatic castration-resistant prostate cancer**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is anticipated to commence on June 1, 2025, with an estimated completion date of May 27, 2027, thus spanning approximately two years.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This initial visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized to receive either the investigational drug or a control, with neither the participants nor the investigators aware of the group assignments, maintaining the double-blind nature of the study.

Throughout the trial, participants will attend regular follow-up visits, which are essential for monitoring safety, assessing adverse events, and evaluating the pharmacokinetics of the drug. These visits will include various assessments such as physical examinations, laboratory tests, and imaging studies, as required by the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, where final evaluations will be conducted to gather comprehensive data on the drug's effects.

The expected duration of participant involvement in the trial is contingent upon the study's timeline and individual response to the treatment. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, withdrawal of consent, or non-compliance with the study protocol. These measures are in place to ensure participant safety and the integrity of the trial data.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be provided. The trial documentation does not include any additional relevant information about drug administration or participant compliance monitoring.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is June 1, 2025, with an anticipated end date of May 27, 2027. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of therapeutic effects alongside safety evaluations. The trial will likely employ standardized methods for measuring and collecting data, which may include laboratory tests and validated scales, to ensure the reliability and validity of the results. The analysis of efficacy will be conducted in accordance with established clinical trial protocols, ensuring that the findings contribute to the understanding of the investigational product's potential benefits.